Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lytix Biopharma AS ( (DE:6BG) ) has issued an update.
Lytix Biopharma AS disclosed that Saturn Invest AS, a close associate of primary insider Brynjar Forbergskog, has subscribed for and been allocated 2,222,222 of the 6,826,200 new shares issued by the company, at a subscription price of NOK 9.00 per share, under a board-authorised share issue approved by an extraordinary general meeting in April 2025. The transaction underscores insider-linked investor participation in Lytix’s ongoing capital raise, which may support the company’s continued clinical development in cancer immunotherapy while triggering standard market abuse and securities disclosure requirements under EU and Norwegian regulations.
More about Lytix Biopharma AS
Lytix Biopharma AS is an Oslo-based clinical-stage biotech company developing immuno-oncology therapies derived from host-defense peptide molecules. Its lead candidate, LTX-315, is a first-in-class oncolytic molecule designed to boost anti-cancer immunity, and the company is building a pipeline targeting multiple cancer indications and treatment settings, both as monotherapy and in combination with other treatments.
Average Trading Volume: 81,220
Current Market Cap: NOK648.5M
Find detailed analytics on 6BG stock on TipRanks’ Stock Analysis page.